The Future of Pediatric Pneumococcal Vaccines

Musey addressed any gaps and limitations that researchers should be focusing on in future studies and what he hopes to see for the future of pneumococcal vaccines and this disease.

Pharmacy Times spoke with Luwy Musey, executive director in biologics and vaccines clinical research at Merck, about the results from two phase 3 pediatric studies surrounding pneumococcal disease that was presented at the IDWeek 2021 conference.

Musey addressed any gaps and limitations that researchers should be focusing on in future studies and what he hopes to see for the future of pneumococcal vaccines and this disease.